For SCHIZOPHRENIA in adultsObserved reductions in PANSS symptom domains in patients on CAPLYTA1

Swipe chart for more

Change from baseline in PANSS
subscale scores at 4 weeks1
This line graph shows changes in MADRS total scores over time from baseline through 26 weeks for patients receiving CAPLYTA 42 mg or placebo.

Limitation: These secondary endpoint and exploratory post hoc analyses were not powered for statistical comparison and are descriptive only; results require cautious interpretation.

Baseline PANSS Total Scores: CAPLYTA 42 mg: 88.1; placebo: 86.3.1

LSM=least squares mean; PANSS=Positive and Negative Syndrome Scale.

The PANSS is a 30-item scale that measures the following symptoms1,2,5*:

Positive Subscale Symptoms:

  • Delusions
  • Hallucinations
  • Conceptual disorganization
  • Excitement
  • Grandiosity
  • Suspiciousness/persecution
  • Hostility

Negative Subscale Symptoms:

  • Blunted affect
  • Emotional withdrawal
  • Poor rapport
  • Passive/apathetic social withdrawal
  • Difficulty in abstract thinking
  • Lack of spontaneity and flow of conversation
  • Stereotyped thinking

General Psychopathology Subscale Symptoms:

  • Somatic concern
  • Anxiety
  • Guilt feelings
  • Tension
  • Mannerisms and posturing
  • Depression
  • Motor retardation
  • Uncooperativeness
  • Unusual thought content
  • Disorientation
  • Poor attention
  • Lack of judgement and insight
  • Disturbance of volition
  • Poor impulse control
  • Preoccupation
  • Active social avoidance

PANSS Prosocial Subscale

The PANSS Prosocial Subscale is a 6-item scale derived from the PANSS total score to measure social functioning. It includes the following symptoms:

  • Hallucinations
  • Suspiciousness/persecution
  • Emotional withdrawal
  • Passive/apathetic social withdrawal
  • Stereotyped thinking
  • Active social avoidance

*Each item is rated by a clinician on a 7-point scale. A score of 1 indicates the absence of symptoms, and a score of 7 indicates extremely severe symptoms. The PANSS total score may range from 30 to 210, with higher scores reflecting greater overall symptom severity.2,5

PANSS=Positive and Negative Syndrome Scale.

References: 1. Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016,79(12):952-961. doi:10.1016/ j.biopsych.2015.08.026 2. CAPLYTA Prescribing Information. 3. Data on File (REF-02886, REF-02887). 4. Correll CU, David RE, Weingart M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(4):349-358. doi:10.1001/jamapsychiatry.2019.4379 5. Shankar G, Nate C. Positive and Negative Syndrome Scale as a long-term outcome measurement tool in patients receiving clozapine ODT- A Pilot Study. Pharm Pract (Granada). 2007;5(1):42-45.